Markers for Primary Immunodeficiency
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What data supports the effectiveness of the treatment for identifying specific markers in primary immunodeficiency?
Research suggests that understanding the genetic basis and using biologic response modifiers (substances that modify immune responses) can improve the treatment of primary immunodeficiency disorders. Advances in identifying genetic defects and immune system regulation have led to better therapies, such as subcutaneous immunoglobulin infusions, which have shown positive results in managing these conditions.12345
What safety data exists for the treatment related to markers for primary immunodeficiency?
How does the treatment for identifying markers in primary immunodeficiency differ from other treatments?
What is the purpose of this trial?
Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopenias has not yet been fully elucidated. Moreover, conventionally employed therapeutic strategies often fail, leading to increased healthcare costs, high morbidity, and even mortality. Therefore, there is a need to establish clinical guidelines for diagnosis and to identify early biomarkers capable of identifying individuals responsive to therapy. Thus, a systematic approach to the study of such pathologies will allow for the identification of early biomarkers and facilitate the development of targeted therapeutic strategies
Eligibility Criteria
This trial is for patients with autoimmune cytopenias, which include conditions like low platelet count, anemia, and low white blood cell count that are resistant to treatment. These patients may also have primary immunodeficiencies (PI).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Identification of specific markers
Analysis of the immunological profile, genetic analysis using next-generation sequencing (NGS) technology, bioinformatic analysis, and functional studies
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Identification of specific markers
Find a Clinic Near You
Who Is Running the Clinical Trial?
Meyer Children's Hospital IRCCS
Lead Sponsor